Insulin glargine

Name: Insulin glargine
Brand: MedChemExpress
SKU: HY-108719
Rating: 4.5 (1 reviews)

製品番号: HY-108719 純度: ≥95.0%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

Insulin glargine 構造式

CAS 番号 : 160337-95-1

容量	価格（税別）	在庫状況	数量
100 U	$80	在庫あり	Estimated Time of Arrival: December 31
300 U	$140	在庫あり	Estimated Time of Arrival: December 31

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Other Forms of Insulin glargine:

Insulin glargine (Standard) お問い合わせ

顧客検証

•Anal Chem. 2025 May 13;97(18):9827-9835. [Abstract]

Akt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Akt Akt1 Akt2 Akt3

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

体外実験

Insulin glargine (10-100 IU/L; 0-72 h) activates Akt in a PI3K-independent manner, thereby promoting the proliferation of bladder cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	T24 bladder cancer cell
Concentration:	0.1, 1, 10 and 100 IU/L
Incubation Time:	72 h
Result:	Promoted T24 cell proliferation at concentrations of 10 IU/L and 100 IU/L. Did not affect cell proliferation at 0.1 IU/L and 1 IU/L.

体内実験

Insulin glargine (2-12.5 IU/kg; subcutaneous injection; 3-12 months) does not present a carcinogenic risk in rodents^[2].
Insulin glargine (450 mg/kg; subcutaneous injection; 6 months) has an improving effect in a mouse model of diabetes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven-week-old male db/db mice^[3]
Dosage:	450 mg/kg
Administration:	Subcutaneous injection (s.c.); 6 months
Result:	Significantly improved glucose tolerance. Upregulated pancreatic β-cell functional genes, such as INS1, Pdx1, Pax4 and Pax6.

臨床実験

分子量

6062.89

分子式

C₂₆₇H₄₀₄N₇₂O₇₈S₆

CAS 番号

160337-95-1

Appearance

Liquid

Color

Colorless to light yellow

Sequence

A-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Gly; B-chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr-Arg-Arg (Disulfide bridge: CysA6-CysA11, CysA7-CysB7, CysA20-CysB19)

Sequence Shortening

A-chain: GIVEQCCTSICSLYQLENYCG; B-chain: FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR (Disulfide bridge: CysA6-CysA11, CysA7-CysB7, CysA20-CysB19)

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at 4°C, do not freeze

純度とドキュメンテーション

純度: 95.00%

Select Batch:

データシート (266 KB) SDS (419 KB)

COA (288 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Liu S, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011 Feb;91(2):177-82. [Content Brief]

[2]. Stammberger I, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002 May-Jun;21(3):171-9. [Content Brief]

[3]. Li Y, et al. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. Med Sci Monit. 2018 May 19;24:3293-3300. [Content Brief]

[4]. Hwang HG, et al. Recombinant Glargine Insulin Production Process Using Escherichia coli. J Microbiol Biotechnol. 2016;26(10):1781-1789. [Content Brief]